Literature DB >> 12492576

Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.

Shima Uneda1, Hiroyuki Hata, Fumihiko Matsuno, Naoko Harada, Yumi Mitsuya, Fumio Kawano, Hiroaki Mitsuya.   

Abstract

Macrophage inflammatory protein-1 alpha (MIP-1alpha) is a chemokine primarily associated with bone absorption. We examined whether MIP-1alpha was produced by purified fresh tumour cells isolated from bone marrow samples from 31 multiple myeloma (MM) patients. High levels of MIP-1alpha were found in supernatants of myeloma cell cultures. Immunohistochemical staining showed MIP-1alpha in the cytoplasm of myeloma cells. MIP-1alpha mRNA expression was detected in 18 of 31 patients. Bone lesions were seen in 16 of the 18 MIP-1alpha-positive patients but only in six of the 13 MIP-1alpha-negative patients (P = 0.0097,chi2-test). The data indicate that MIP-1alpha is produced by myeloma cells and possibly plays a role in the pathogenesis of bone lesions in MM patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12492576     DOI: 10.1046/j.1365-2141.2003.04040.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daiichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 2.  Multiple Myeloma and Bone: The Fatal Interaction.

Authors:  Silvia Marino; G David Roodman
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

3.  CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Authors:  Daniel J Dairaghi; Babatunde O Oyajobi; Anjana Gupta; Brandon McCluskey; Shichang Miao; Jay P Powers; Lisa C Seitz; Yu Wang; Yibin Zeng; Penglie Zhang; Thomas J Schall; Juan C Jaen
Journal:  Blood       Date:  2012-05-22       Impact factor: 22.113

4.  Bone anabolic agents for the treatment of multiple myeloma.

Authors:  Sonia Vallet; Noopur Raje
Journal:  Cancer Microenviron       Date:  2011-12-03

Review 5.  Chemokines in multiple myeloma.

Authors:  Rohit Aggarwal; Irene M Ghobrial; G David Roodman
Journal:  Exp Hematol       Date:  2006-10       Impact factor: 3.084

6.  C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.

Authors:  Matthew W Anderson; Shuchun Zhao; Weiyun Z Ai; Robert Tibshirani; Ronald Levy; Izidore S Lossos; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2010-03       Impact factor: 2.493

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

8.  Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

Authors:  Wenjie He; Amitabha Mazumder; Tuere Wilder; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-05-16       Impact factor: 5.191

9.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

10.  PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Authors:  S Fujiwara; Y Kawano; H Yuki; Y Okuno; K Nosaka; H Mitsuya; H Hata
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.